Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation

BACKGROUND: Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to progression such as clinical patterns of progression (dramatic, gradual, and local) with the prognosis of NSCLC patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Thorac Dis
Asıl Yazarlar: Barrón, Feliciano, Cardona, Andrés F., Corrales, Luis, Ramirez-Tirado, Laura-Alejandra, Caballe-Perez, Enrique, Sanchez, Gisela, Flores-Estrada, Diana, Zatarain-Barrón, Zyanya Lucia, Arrieta, Oscar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2018
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5949490/
https://ncbi.nlm.nih.gov/pubmed/29850120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.03.106
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller